Adherence to Antihypertensive Treatment and Associated Factors in Central Ethiopia.

Journal

International journal of hypertension

ISSN: 2090-0384

Titre abrégé: Int J Hypertens

Pays: United States

ID NLM: 101538881

Informations de publication

Date de publication:
2020

Historique:

received: 25 04 2020

revised: 28 09 2020

accepted: 08 10 2020

entrez: 5 11 2020

pubmed: 6 11 2020

medline: 6 11 2020

Statut: epublish

Résumé

Adherence to treatment is a primary determinant of treatment success. Nonadherence attenuates clinical benefits to the recipients of the treatment. However, monitoring adherence to long treatment regimens is not given due emphasis in low-income contexts. This study aimed to assess adherence to antihypertensive treatment and factors associated with it in Central Ethiopia. This is an institution-based cross-sectional study conducted in 4 public hospitals in Central Ethiopia from December 4, 2016, to September 25, 2017. The Morisky Medication Adherence Scale (MMAS-8) was used to assess the level of adherence. The Revised Illness Perception Questionnaire (IPQ-R) was used to assess illness perception. The MMAS-8 score ranges from 0 to 8, a score of 8 reflects high adherence, 6 to 7 medium adherence, and <6 low adherence. A total of 989 hypertensive patients participated in the study, of which 36.0% were assessed to have high adherence, 31.7% medium adherence, and 32.3% low adherence. We found that treatment adherence was significantly and positively associated with having family support (AOR: 1.65; 95% CI = 1.23, 2.22), high perception about consequences of hypertension (AOR: 1.51; 95% CI = 1.17, 1.95), and high perception about the severity of the disease (AOR: 1.42; 95% CI = 1.09, 1.86). The treatment adherence to antihypertensive medications is low in Central Ethiopia. Engaging family members in the treatment plan and improving patients' understanding of the illness are critical in achieving high adherence to medication in this context.

Sections du résumé

BACKGROUND BACKGROUND

METHOD METHODS

This is an institution-based cross-sectional study conducted in 4 public hospitals in Central Ethiopia from December 4, 2016, to September 25, 2017. The Morisky Medication Adherence Scale (MMAS-8) was used to assess the level of adherence. The Revised Illness Perception Questionnaire (IPQ-R) was used to assess illness perception. The MMAS-8 score ranges from 0 to 8, a score of 8 reflects high adherence, 6 to 7 medium adherence, and <6 low adherence.

RESULTS RESULTS

A total of 989 hypertensive patients participated in the study, of which 36.0% were assessed to have high adherence, 31.7% medium adherence, and 32.3% low adherence. We found that treatment adherence was significantly and positively associated with having family support (AOR: 1.65; 95% CI = 1.23, 2.22), high perception about consequences of hypertension (AOR: 1.51; 95% CI = 1.17, 1.95), and high perception about the severity of the disease (AOR: 1.42; 95% CI = 1.09, 1.86).

CONCLUSION CONCLUSIONS

The treatment adherence to antihypertensive medications is low in Central Ethiopia. Engaging family members in the treatment plan and improving patients' understanding of the illness are critical in achieving high adherence to medication in this context.

Identifiants

DOI: 10.1155/2020/9540810 PMID: 33149946 PMC: PMC7603603

pubmed: 33149946

doi: 10.1155/2020/9540810

pmc: PMC7603603

doi:

Types de publication

Journal Article

Langues

eng

Pagination

9540810

Informations de copyright

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Clin Ther. 2007 May;29(5):972-984

pubmed: 17697916

Niger J Med. 2005 Jan-Mar;14(1):55-7

pubmed: 15832644

Lancet. 2016 Oct 8;388(10053):1603-1658

pubmed: 27733283

Hypertens Res. 2013 Nov;36(11):1000-5

pubmed: 23966057

J Clin Nurs. 2009 Aug;18(15):2234-44

pubmed: 19583655

Diabetes Care. 2011 Feb;34(2):338-40

pubmed: 21270191

Can J Cardiol. 2006 May 15;22(7):599-603

pubmed: 16755315

PLoS One. 2015 Apr 24;10(4):e0125210

pubmed: 25909382

N Engl J Med. 2017 Aug 24;377(8):733-744

pubmed: 28834483

Cardiovasc J Afr. 2015 Jan-Feb;26(1):29-33

pubmed: 25784314

Am J Hypertens. 2010 Feb;23(2):155-60

pubmed: 19927135

QJM. 2013 Oct;106(10):909-14

pubmed: 23696676

BMC Health Serv Res. 2012 Jun 14;12:98

pubmed: 22510235

JAMA. 2014 Feb 5;311(5):507-20

pubmed: 24352797

Med Care. 2005 Jun;43(6):521-30

pubmed: 15908846

Am J Geriatr Pharmacother. 2011 Feb;9(1):11-23

pubmed: 21459305

Int J Health Sci (Qassim). 2017 Sep-Oct;11(4):47-52

pubmed: 29085268

J Psychosom Res. 2011 Feb;70(2):179-87

pubmed: 21262421

PLoS One. 2013 Dec 02;8(12):e80633

pubmed: 24312488

BMC Public Health. 2012 Apr 10;12:282

pubmed: 22490130

J Clin Nurs. 2012 Jul;21(13-14):1816-24

pubmed: 22672451

Clinicoecon Outcomes Res. 2011;3:47-54

pubmed: 21935332

Women Health. 2002;35(1):83-96

pubmed: 11942471

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):181-7

pubmed: 21857529

Med Clin North Am. 2009 May;93(3):753-69

pubmed: 19427503

Nurs Forum. 2009 Jan-Mar;44(1):25-36

pubmed: 19187051

Eur Heart J. 2012 Aug;33(16):2088-97

pubmed: 22511654

Am J Gastroenterol. 2010 Mar;105(3):525-39

pubmed: 19997092

Ann Med Health Sci Res. 2015 May-Jun;5(3):173-8

pubmed: 26097758

Indian J Community Med. 2015 Jan-Mar;40(1):33-7

pubmed: 25657510

Curr Opin Cardiol. 2004 Jul;19(4):357-62

pubmed: 15218396

N Engl J Med. 2017 Aug 24;377(8):745-755

pubmed: 28834469

Clin Med (Lond). 2006 Nov-Dec;6(6):536-9

pubmed: 17228551

Circulation. 2009 Oct 20;120(16):1598-605

pubmed: 19805653

Ann Med Health Sci Res. 2014 Nov;4(6):922-7

pubmed: 25506487

BMJ. 2012 Jul 09;345:e3953

pubmed: 22777025

J Clin Hypertens (Greenwich). 2008 May;10(5):348-54

pubmed: 18453793

Circulation. 2016 Aug 9;134(6):441-50

pubmed: 27502908

J Public Health (Oxf). 2005 Sep;27(3):281-91

pubmed: 15870099

Patient Educ Couns. 2015 May;98(5):669-73

pubmed: 25746128